Literature DB >> 20601653

Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis.

Daniela Braconi1, Marcella Laschi, Loredana Amato, Giulia Bernardini, Lia Millucci, Roberto Marcolongo, Giovanni Cavallo, Adriano Spreafico, Annalisa Santucci.   

Abstract

OBJECTIVES: Alkaptonuria (AKU) is a rare genetic disease associated with deficient homogentisate 1,2-dioxygenase activity in the liver. This leads to the accumulation of homogentisic acid (HGA) and its oxidized/polymerized products in connective tissues, which in turn become characterized by the presence of melanin-like pigments (ochronosis). Since at present, further studies are necessary to support the use of drugs for the treatment of AKU, we investigated the effects of various anti-oxidants in counteracting melanin-like pigmentation and oxidative stress related to HGA and its metabolites.
METHODS: We set up an in vitro model using human serum treated with 0.33 mM HGA and tested the anti-oxidants ascorbic acid, N-acetylcysteine, phytic acid (PHY), taurine (TAU), ferulic acid (FER) and lipoic acid (LIP) for their ability to prevent or delay the production of melanin-like pigments, as well as to reduce oxidative post-translational modifications of proteins. Monitoring of intrinsic fluorescence of HGA-induced melanin-like pigments was used to evaluate the efficacy of compounds.
RESULTS: Our model allowed us to prove efficacy especially for PHY, TAU, LIP and FER in counteracting the production of HGA-induced melanin-like pigments and protein oxidation induced by HGA and its metabolites.
CONCLUSIONS: Our model allows the opening of new anti-oxidant therapeutic strategies to treat alkaptonuric ochronosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601653     DOI: 10.1093/rheumatology/keq175

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  18 in total

1.  The Pigment in Alkaptonuria Relationship to Melanin and Other Coloured Substances: A Review of Metabolism, Composition and Chemical Analysis.

Authors:  N B Roberts; S A Curtis; A M Milan; L R Ranganath
Journal:  JIMD Rep       Date:  2015-06-21

Review 2.  Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.

Authors:  P Malaspina; J-B Roullet; P L Pearl; G R Ainslie; K R Vogel; K M Gibson
Journal:  Neurochem Int       Date:  2016-06-14       Impact factor: 3.921

3.  Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis.

Authors:  Daniela Braconi; Claretta Bianchini; Giulia Bernardini; Marcella Laschi; Lia Millucci; Adriano Spreafico; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2011-08-27       Impact factor: 4.982

Review 4.  Amyloidosis in alkaptonuria.

Authors:  Lia Millucci; Daniela Braconi; Giulia Bernardini; Pietro Lupetti; Josef Rovensky; Lakshminaryan Ranganath; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-04-14       Impact factor: 4.982

5.  Biochemical and proteomic characterization of alkaptonuric chondrocytes.

Authors:  Daniela Braconi; Giulia Bernardini; Claretta Bianchini; Marcella Laschi; Lia Millucci; Loredana Amato; Laura Tinti; Tommaso Serchi; Federico Chellini; Adriano Spreafico; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

6.  Interactive alkaptonuria database: investigating clinical data to improve patient care in a rare disease.

Authors:  Vittoria Cicaloni; Ottavia Spiga; Giovanna Maria Dimitri; Rebecca Maiocchi; Lia Millucci; Daniela Giustarini; Giulia Bernardini; Andrea Bernini; Barbara Marzocchi; Daniela Braconi; Annalisa Santucci
Journal:  FASEB J       Date:  2019-08-28       Impact factor: 5.834

7.  Secondary amyloidosis in an alkaptonuric aortic valve.

Authors:  Lia Millucci; Lorenzo Ghezzi; Daniela Braconi; Marcella Laschi; Michela Geminiani; Loredana Amato; Maurizio Orlandini; Chiara Benvenuti; Giulia Bernardini; Annalisa Santucci
Journal:  Int J Cardiol       Date:  2014-01-04       Impact factor: 4.164

8.  Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.

Authors:  Giulia Bernardini; Marcella Laschi; Michela Geminiani; Daniela Braconi; Elisa Vannuccini; Pietro Lupetti; Fabrizio Manetti; Lia Millucci; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-03-12       Impact factor: 4.982

9.  Alkaptonuria is a novel human secondary amyloidogenic disease.

Authors:  Lia Millucci; Adriano Spreafico; Laura Tinti; Daniela Braconi; Lorenzo Ghezzi; Eugenio Paccagnini; Giulia Bernardini; Loredana Amato; Marcella Laschi; Enrico Selvi; Mauro Galeazzi; Alessandro Mannoni; Maurizio Benucci; Pietro Lupetti; Federico Chellini; Maurizio Orlandini; Annalisa Santucci
Journal:  Biochim Biophys Acta       Date:  2012-07-28

10.  Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.

Authors:  Adriano Spreafico; Lia Millucci; Lorenzo Ghezzi; Michela Geminiani; Daniela Braconi; Loredana Amato; Federico Chellini; Bruno Frediani; Elena Moretti; Giulia Collodel; Giulia Bernardini; Annalisa Santucci
Journal:  Rheumatology (Oxford)       Date:  2013-05-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.